中国麻风皮肤病杂志 ›› 2022, Vol. 38 ›› Issue (4): 232-235.doi: 10.12144/zgmfskin202204232

• 临床研究 • 上一篇    下一篇

卡瑞利珠单抗引起的反应性毛细血管增生症二例

张倩倩1,戚兆亮2,杨惠1,王晓燕3   

  1. 1解放军960医院皮肤科，泰安，271000；2解放军960医院呼吸科，泰安，271000；3解放军960医院病理科，泰安，271000
  • 出版日期:2022-04-15 发布日期:2022-02-10
  • 通讯作者: 戚兆亮，E-mail: zhaoliang_qi@163.com

Reactive cutaneous capillary endothelial proliferation caused by PD-1 inhibitor camrelizumab: two cases report

ZHANG Qianqian1, QI Zhaoliang2, YANG Hui1, WANG Xiaoyan3   

  1. 1 Department of Dermatology, 960 Hospital of Chinese PLA, Taian 271000, China; 2 Department of Respiratory, 960 Hospital of Chinese PLA, Taian 271000, China; 3 Department of Pathology, 960 Hospital of Chinese PLA, Taian 271000, China
  • Online:2022-04-15 Published:2022-02-10
  • Contact: QI Zhaoliang, E-mail: zhaoliang_qi@163.com

PDF (PC)

283

摘要： 2例患者分别在首次使用卡瑞利珠单抗2周和3周后出现头面部、躯干和四肢皮肤的血管赘生物，部分皮损伴破溃出血，遂行手术切除，术后行组织病理活检示：肉芽组织型血管瘤。诊断：反应性毛细血管增生症。

关键词: 卡瑞利珠单抗, PD-1抑制剂, 反应性毛细血管增生症, 免疫治疗相关不良反应

Abstract: Two patients with lung cancers presented with cutaneous capillary endothelial proliferation on the head, face, trunk, and extremities after the first treatment with camrelizumab for 2 or 3 weeks. Some lesions which were accompanied with ulceration and bleeding were treated with surgical resections. The histological feature was in accordance with granulomatous hemangioma. The diagnosis of reactive cutaneous capillary endothelial proliferation was made.

Key words: camrelizumab, PD-1 inhibitor, reactive cutaneous capillary endothelial proliferation, Immune-related adverse events